{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:30:05Z","timestamp":1789745405556,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"PharmaEssentia Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00277-024-05912-8","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T10:02:17Z","timestamp":1723716137000},"page":"3573-3583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early\/lower-risk primary myelofibrosis"],"prefix":"10.1007","volume":"103","author":[{"given":"Ghaith","family":"Abu-Zeinah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichung Joe","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleh","family":"Zagrijtschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"issue":"2","key":"5912_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8(2):15. https:\/\/doi.org\/10.1038\/s41408-018-0054-y","journal-title":"Blood Cancer J"},{"issue":"6","key":"5912_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.leukres.2016.12.0012","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F et al (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31(6):737\u2013740. https:\/\/doi.org\/10.1016\/j.leukres.2016.12.0012","journal-title":"Leuk Res"},{"issue":"5","key":"5912_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/0008-5472.CAN-21-2930","volume":"82","author":"A Tefferi","year":"2022","unstructured":"Tefferi A, Gangat N, Pardanani A, Crispino JD (2022) Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. Cancer Res 82(5):749\u2013763. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2930","journal-title":"Cancer Res"},{"issue":"10","key":"5912_CR4","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","volume":"96","author":"D Kc","year":"2017","unstructured":"Kc D, Falchi L, Verstovsek S (2017) The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: A review. Ann Hematol 96(10):1595\u20131604. https:\/\/doi.org\/10.1007\/s00277-017-3099-2","journal-title":"Ann Hematol"},{"issue":"12","key":"5912_CR5","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.3390\/cells10123551","volume":"10","author":"J Baumeister","year":"2021","unstructured":"Baumeister J, Chatain N, Sofias AM (2021) Progression of myeloproliferative neoplasms (MPN): diagnostic and therapeutic perspectives. Cells 10(12):3551. https:\/\/doi.org\/10.3390\/cells10123551","journal-title":"Cells"},{"issue":"4","key":"5912_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778\u2013782. https:\/\/doi.org\/10.1182\/blood-2009-08-238956","journal-title":"Blood"},{"key":"5912_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:437\u2013438. https:\/\/doi.org\/10.1038\/sj.leu.2404914","journal-title":"Leukemia"},{"issue":"2","key":"5912_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.hoc.2020.12.006","volume":"35","author":"R Mesa","year":"2021","unstructured":"Mesa R, Palmer J, Eckert R, Huberty J (2021) Quality of Life in Myeloproliferative Neoplasms: Symptoms and Management Implications. Hematol Oncol Clin North Am 35(2):375\u2013390. https:\/\/doi.org\/10.1016\/j.hoc.2020.12.006","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"5912_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392\u2013397. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol"},{"issue":"24","key":"5912_CR10","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","volume":"129","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Pacilli A, Rotunno G et al (2017) Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood 129(24):3227\u20133236. https:\/\/doi.org\/10.1182\/blood-2017-01-761999","journal-title":"Blood"},{"issue":"4","key":"5912_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hon.2619","volume":"37","author":"F Palandri","year":"2019","unstructured":"Palandri F, Palumbo GA, Abruzzese E et al (2019) Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematol Oncol 37(4):418\u2013423. https:\/\/doi.org\/10.1002\/hon.2619","journal-title":"Hematol Oncol"},{"issue":"9","key":"5912_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajh.24788","volume":"92","author":"G Jeryczynski","year":"2017","unstructured":"Jeryczynski G, Thiele J, Gisslinger B et al (2017) Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnosis criteria on the outcome of the disease. Am J Hematol 92(9):885\u2013891. https:\/\/doi.org\/10.1002\/ajh.24788","journal-title":"Am J Hematol"},{"issue":"7","key":"5912_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/ajh.23217","volume":"87","author":"V Buxhofer-Ausch","year":"2012","unstructured":"Buxhofer-Ausch V, Gisslinger H, Thiele J et al (2012) Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 87(7):669\u2013672. https:\/\/doi.org\/10.1002\/ajh.23217","journal-title":"Am J Hematol"},{"issue":"Suppl","key":"5912_CR14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/01.HS9.0000847116.74895.d8","volume":"6","author":"AT Gerds","year":"2022","unstructured":"Gerds AT, Mesa R, Burke JM et al (2022) P1062: A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera: an analysis of data from the REVEAL study. Hemasphere 6(Suppl):952\u2013953. https:\/\/doi.org\/10.1097\/01.HS9.0000847116.74895.d8","journal-title":"Hemasphere"},{"key":"5912_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040620719870052","volume":"10","author":"P Bose","year":"2019","unstructured":"Bose P, Verstovsek S (2019) Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol 10:1\u201313. https:\/\/doi.org\/10.1177\/2040620719870052","journal-title":"Ther Adv Hematol"},{"issue":"14","key":"5912_CR16","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/cncr.34222","volume":"128","author":"JO Mascarenhas","year":"2022","unstructured":"Mascarenhas JO, Verstovsek S (2022) The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer 128(14):2717\u20132727. https:\/\/doi.org\/10.1002\/cncr.34222","journal-title":"Cancer"},{"key":"5912_CR17","unstructured":"INREBIC\u00ae (fedratinib) Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212327s004lbl.pdf. Accessed 29 May 2024"},{"issue":"2","key":"5912_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.2023022345","volume":"143","author":"A Rampotas","year":"2024","unstructured":"Rampotas A, Carter-Brzezinski L, Somervaille TCP et al (2024) Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood 143(2):178\u2013182. https:\/\/doi.org\/10.1182\/blood.2023022345","journal-title":"Blood"},{"key":"5912_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41408-020-0290-9","volume":"10","author":"T Barbui","year":"2020","unstructured":"Barbui T, Thiele J, Ferrari A et al (2020) The new WHO classification for essential thrombocythemia calls for revision of available evidences. Blood Cancer J 10:22. https:\/\/doi.org\/10.1038\/s41408-020-0290-9","journal-title":"Blood Cancer J"},{"key":"5912_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132\u20131137. https:\/\/doi.org\/10.1056\/NEJM199504273321704","journal-title":"N Engl J Med"},{"key":"5912_CR21","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/ajh.24851","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Finazzi G et al (2017) A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol 92:1131\u20131136. https:\/\/doi.org\/10.1002\/ajh.24851","journal-title":"Am J Hematol"},{"key":"5912_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41408-018-0161-9","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM (2018) Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood Cancer J 8:124. https:\/\/doi.org\/10.1038\/s41408-018-0161-9","journal-title":"Blood Cancer J"},{"issue":"11","key":"5912_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","volume":"8","author":"V De Stefano","year":"2018","unstructured":"De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, Vannucchi AM et al (2018) Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district Pooled analysis of 1500 cases. Blood Cancer J 8(11):112. https:\/\/doi.org\/10.1038\/s41408-018-0151-y","journal-title":"Blood Cancer J"},{"issue":"3","key":"5912_CR24","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomized, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7(3):e196-208. https:\/\/doi.org\/10.1016\/S2352-3026(19)30236-4","journal-title":"Lancet Haematol"},{"key":"5912_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05665-4","author":"JJ Kiladjian","year":"2024","unstructured":"Kiladjian JJ, Marin FF, Al-Ali HK et al (2024) ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-024-05665-4","journal-title":"Ann Hematol"},{"issue":"19","key":"5912_CR26","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT et al (2022) A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 139(19):2931\u20132941. https:\/\/doi.org\/10.1182\/blood.2021012743","journal-title":"Blood"},{"issue":"24","key":"5912_CR27","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","volume":"117","author":"RT Silver","year":"2011","unstructured":"Silver RT, Vandris K, Goldman JJ (2011) Recombinant interferon-\u03b1 may retard progression of early primary myelofibrosis: a preliminary report. Blood 117(24):6669\u20136672. https:\/\/doi.org\/10.1182\/blood-2010-11-320069","journal-title":"Blood"},{"issue":"2","key":"5912_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2141.2009.07745.x","volume":"146","author":"JC Ianotto","year":"2009","unstructured":"Ianotto JC, Kiladjian JJ, Demory JL, Roy L, Boyer F, Rey J, Dupriez B et al (2009) PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d\u2019Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes My\u00e9loprolif\u00e9ratifs (FIM). Br J Haematol 146(2):223\u2013225. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07745.x","journal-title":"Br J Haematol"},{"issue":"14","key":"5912_CR29","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/cncr.30679","volume":"123","author":"RT Silver","year":"2017","unstructured":"Silver RT, Barel AC, Lascu E et al (2017) The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis. Cancer 123(14):2680\u20132687. https:\/\/doi.org\/10.1002\/cncr.30679","journal-title":"Cancer"},{"issue":"10","key":"5912_CR30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","volume":"28","author":"M Pizzi","year":"2015","unstructured":"Pizzi M, Silver RT, Barel A et al (2015) Recombinant interferon-\u03b1 in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol 28(10):1315\u20131323. https:\/\/doi.org\/10.1038\/modpathol.2015.93","journal-title":"Mod Pathol"},{"key":"5912_CR31","doi-asserted-by":"publisher","unstructured":"Silver RT, Kiladjian JJ, Hasselbalch HC (2013) Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 49\u201358. https:\/\/doi.org\/10.1586\/ehm.12.69","DOI":"10.1586\/ehm.12.69"},{"key":"5912_CR32","unstructured":"NCCN. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 3. 2022. Accessed 29 May 2024"},{"issue":"5","key":"5912_CR33","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/bcp.15176","volume":"88","author":"YW Huang","year":"2022","unstructured":"Huang YW, Qin A, Fang J et al (2022) Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Br J Clin Pharmacol 88(5):2396\u20132407. https:\/\/doi.org\/10.1111\/bcp.15176","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"5912_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","volume":"41","author":"N Miyachi","year":"2021","unstructured":"Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A (2021) Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin Drug Investig 41(4):391\u2013404. https:\/\/doi.org\/10.1007\/s40261-021-01026-5","journal-title":"Clin Drug Investig"},{"key":"5912_CR35","unstructured":"United States Food & Drug Administration. FDA news release: FDA approves treatment for rare blood disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-rare-blood-disease. Accessed 21 December 2021"},{"key":"5912_CR36","unstructured":"European Medicines Agency. Besremi (ropeginterferon alfa-2b). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/ EPAR\/besremi. Accessed 15 May 2024"},{"issue":"27","key":"5912_CR37","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.2217\/fon-2022-0596","volume":"18","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Komatsu N, Gill H et al (2022) SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol 18(27):2999\u20133009. https:\/\/doi.org\/10.2217\/fon-2022-0596","journal-title":"Future Oncol"},{"issue":"11","key":"5912_CR38","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/jgh3.12825","volume":"6","author":"CY Chen","year":"2022","unstructured":"Chen CY, Chuang WL, Qin A et al (2022) A phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C. JGH Open 6(11):782\u2013791. https:\/\/doi.org\/10.1002\/jgh3.12825","journal-title":"JGH Open"},{"key":"5912_CR39","doi-asserted-by":"publisher","unstructured":"Qin A, Huang YW, Chen PJ. A validated, new-generation pegylated interferon therapy for chronic hepatitis B and possibly D. CTGH. 2022. https:\/\/doi.org\/10.32474\/CTGH.2022.04.000178.","DOI":"10.32474\/CTGH.2022.04.000178"},{"key":"5912_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s44276-024-00076-4","volume":"2","author":"K Kirito","year":"2024","unstructured":"Kirito K, Qin A, Suo S et al (2024) Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia. BJC Rep 2:51. https:\/\/doi.org\/10.1038\/s44276-024-00076-4","journal-title":"BJC Rep"},{"key":"5912_CR41","doi-asserted-by":"publisher","unstructured":"Suo S, Fu R, Qin A et al (2024) Effective management of polycythemia vera with ropeginterferon alfa-2b. J Hematol 13(1\u20132):12\u201322. https:\/\/doi.org\/10.14740\/jh1245","DOI":"10.14740\/jh1245"},{"issue":"5","key":"5912_CR42","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P et al (2022) Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36(5):1408\u20131411. https:\/\/doi.org\/10.1038\/s41375-022-01528-x","journal-title":"Leukemia"},{"key":"5912_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.03.005","author":"A Qin","year":"2024","unstructured":"Qin A (2024) Mechanism of action of ropeginterferon alfa-2b in polycythemia vera treatment. Clin Thera. https:\/\/doi.org\/10.1016\/j.clinthera.2024.03.005","journal-title":"Clin Thera"},{"issue":"2","key":"5912_CR44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A et al (2022) Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol 116(2):215\u2013227. https:\/\/doi.org\/10.1007\/s12185-022-03341-9","journal-title":"Int J Hematol"},{"issue":"1","key":"5912_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A et al (2023) A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol 12(1):55. https:\/\/doi.org\/10.1186\/s40164-023-00415-0","journal-title":"Exp Hematol Oncol"},{"issue":"Supplement 1","key":"5912_CR46","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1182\/blood-2023-180922","volume":"142","author":"H Gill","year":"2023","unstructured":"Gill H, Au L, Leung GMK et al (2023) Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low\/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification. Blood 142(Supplement 1):4562. https:\/\/doi.org\/10.1182\/blood-2023-180922","journal-title":"Blood"},{"issue":"suppl 1","key":"5912_CR47","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1182\/blood-2023-184431","volume":"142","author":"SE Lee","year":"2023","unstructured":"Lee SE, Yoon SS, Yang DH (2023) Single-arm, open-label, multicenter study to assess molecular response of P1101 therapy in patients with polycythemia vera and elevated hematocrit: Results from 12-month core study. Blood 142(suppl 1):4575. https:\/\/doi.org\/10.1182\/blood-2023-184431","journal-title":"Blood"},{"key":"5912_CR48","doi-asserted-by":"publisher","first-page":"1109866","DOI":"10.3389\/fonc.2023.1109866","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J (2023) An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol 13:1109866. https:\/\/doi.org\/10.3389\/fonc.2023.1109866","journal-title":"Front Oncol"},{"issue":"8","key":"5912_CR49","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395\u20131398. https:\/\/doi.org\/10.1182\/blood-2013-03-488098","journal-title":"Blood"},{"key":"5912_CR50","doi-asserted-by":"publisher","unstructured":"Barbui T, Vannucchi AM, De Stefano V et al (2023) Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid. 2(6):EVIDoa2200335. https:\/\/doi.org\/10.1056\/EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335"},{"issue":"4","key":"5912_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N et al (2019) 2023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 94(4):599\u2013610","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"5912_CR52","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V et al (2013) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 31(10):1285\u20131292. https:\/\/doi.org\/10.1200\/JCO.2012.44.4489","journal-title":"J Clin Oncol"},{"issue":"9","key":"5912_CR53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"5912_CR54","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/sim.1688","volume":"23","author":"YHJ Chen","year":"2004","unstructured":"Chen YHJ, Gordon DDL, LKK, (2004) Increasing the sample size when the unblinded interim result is promising. Statist Med 23:1023\u20131038. https:\/\/doi.org\/10.1002\/sim.1688","journal-title":"Statist Med"},{"key":"5912_CR55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cct.2015.12.007","volume":"47","author":"WJ Shih","year":"2015","unstructured":"Shih WJ, Li G, Wang Y (2015) Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches. Contemp Clin Trials 47:40\u20138. https:\/\/doi.org\/10.1016\/j.cct.2015.12.007","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"5912_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jha2.854","volume":"5","author":"ST Oh","year":"2024","unstructured":"Oh ST, Verstovsek S, Gupta V et al (2024) Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. EJHaem 5(1):105\u2013116. https:\/\/doi.org\/10.1002\/jha2.854","journal-title":"EJHaem"},{"issue":"9","key":"5912_CR57","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","volume":"35","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Krichevsky S, Cruz T et al (2021) Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia 35(9):2592\u20132601. https:\/\/doi.org\/10.1038\/s41375-021-01183-8","journal-title":"Leukemia"},{"key":"5912_CR58","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN (2023) JAK2V617F allele burden in polycythemia vera: burden of proof. Blood 141:1934\u20131942. https:\/\/doi.org\/10.1182\/blood.2022017697","journal-title":"Blood"},{"issue":"10","key":"5912_CR59","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2023) Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia 37(10):2129\u20132132. https:\/\/doi.org\/10.1038\/s41375-023-02008-6","journal-title":"Leukemia"},{"key":"5912_CR60","doi-asserted-by":"publisher","first-page":"1173467","DOI":"10.3389\/fonc.2023.1173467","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A (2023) An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Front Oncol 13:1173467. https:\/\/doi.org\/10.3389\/fonc.2023.1173467","journal-title":"Front Oncol"},{"issue":"11","key":"5912_CR61","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1089\/10799900260442511","volume":"22","author":"C Kaynor","year":"2002","unstructured":"Kaynor C, Xin M, Wakefield J, Barsoum J, Qin XQ (2002) Direct evidence that IFN-beta functions as a tumor-suppressor protein. J Interferon Cytokine Res 22(11):1089\u20131098. https:\/\/doi.org\/10.1089\/10799900260442511","journal-title":"J Interferon Cytokine Res"},{"issue":"10","key":"5912_CR62","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/j.clml.2020.05.018","volume":"20","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Giri S, Wang R et al (2020) Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk 20(10):e712\u2013e723. https:\/\/doi.org\/10.1016\/j.clml.2020.05.018","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05912-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05912-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05912-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:19:25Z","timestamp":1724836765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05912-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5912"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05912-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be approved by the appropriate institutional review board or ethic committee of participating clinical sites and will follow the principles of the Declaration of Helsinki for all human experimental investigations. Informed consent will be obtained from all the participating patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical disclosure"}},{"value":"The trial is registered at <i>clinicaltrials.gov<\/i>. The registration number is NCT06468033.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G Abu-Zeinah: no competing interests to declare; A Qin: Currently working for PharmaEssentia and serving as the company\u2019s chief medical officer; H Gill: Consulting fees\/Speaker fees from Abbvie, Bristol Myers Squibb, GSK, MSD, Novartis, PharmaEssentia Corporation and Pfizer, Advisory board for Abbvie, Bristol Myers Squibb, GSK, Novartis, PharmaEssentia Corporation and Pfizer, Research support from Celgene, MSD, Novartis and PharmaEssentia Corporation, Conference support from Bristol Myers Squibb, MSD, Novartis, Otsuka, PharmaEssentia and Pfizer; N Komatsu: Served as a board member of and received funding for medical writing and article processing charges from PharmaEssentia Japan K.K. and received research funding from Meiji Seika Pharma Co., Ltd. and consulting fees from Torii Pharmaceutical Co., Ltd.; J Mascarenhas: Research support provided to the institution from Incyte, Novartis, Merck, CTI Bio, Roche, Kartos, Abbvie, Geron, BMS, and PharmaEssentia, Consulting fees from Incyte, Novartis, Roche, CTI Bio, Morphosys, BMS, Galecto, Karyopharm, Kartos, Abbvie, Sierra Onc, GSK, and PharmaEssentia; W Shih: Serving as a consultant of PharmaEssentia; O Zagrijtschuk is employed by PharmaEssentia USA; T Sato is employed by PharmaEssentia Japan K.K.; K Shimoda is a consultant for Sierra Oncology, Inc. and reports research funding from AbbVie G.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PharmaEssentia Japan K.K., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.and honoraria from Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K.; and is a member of an advisory committee for AbbVie G.K.; RT Silver: no competing interests to declare; R Mesa: Consultant (Honoraria) over past 3\u00a0years: Abbvie, Blueprint, BMS, CTI, Genentech, Geron, GSK, Incyte, Novartis, Sierra, Sierra Oncology, Telios; Research Support: Abbvie, Blueprint, BMS, CTI, Genentech, Incyte, Morphosys, Sierra.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}